THE WOODLANDS, Texas, Sept. 15 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc., a biopharmaceutical company focused on
discovering breakthrough treatments for human disease, obtained favorable
results from recently completed Phase 1 studies of LX4211 and announced today
that it has initiated a Phase 2 clinical trial of the drug candidate in
patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small
molecule drug candidate that inhibits the sodium glucose transporter 2
(SGLT2). LX4211 is Lexicon's fourth drug candidate currently being tested in
Phase 2 clinical trials.
